Literature DB >> 25633595

Regenerative medicine: targeted genome editing in vivo.

Lixia Wang1, Jun Wu2, Weiwei Fang3, Guang-Hui Liu4, Juan Carlos Izpisua Belmonte2.   

Abstract

The CRISPR/Cas system has proven to be a powerful gene editing tool both in vitro and in vivo. A recent flurry of studies of in vivo gene editing using the CRISPR/Cas system bring bright prospects in creating animal models and targeted gene therapy of human genetic diseases.

Entities:  

Mesh：

Year:  2015        PMID： 25633595      PMCID： PMC4349243          DOI： 10.1038/cr.2015.11

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  12 in total

1.  CRISPR-Cas9 knockin mice for genome editing and cancer modeling.

Authors:  Randall J Platt; Sidi Chen; Yang Zhou; Michael J Yim; Lukasz Swiech; Hannah R Kempton; James E Dahlman; Oren Parnas; Thomas M Eisenhaure; Marko Jovanovic; Daniel B Graham; Siddharth Jhunjhunwala; Matthias Heidenreich; Ramnik J Xavier; Robert Langer; Daniel G Anderson; Nir Hacohen; Aviv Regev; Guoping Feng; Phillip A Sharp; Feng Zhang
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

2.  Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells.

Authors:  Yuxuan Wu; Hai Zhou; Xiaoying Fan; Ying Zhang; Man Zhang; Yinghua Wang; Zhenfei Xie; Meizhu Bai; Qi Yin; Dan Liang; Wei Tang; Jiaoyang Liao; Chikai Zhou; Wujuan Liu; Ping Zhu; Hongshan Guo; Hong Pan; Chunlian Wu; Huijuan Shi; Ligang Wu; Fuchou Tang; Jinsong Li
Journal:  Cell Res       Date:  2014-12-05       Impact factor: 25.617

3.  In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9.

Authors:  Lukasz Swiech; Matthias Heidenreich; Abhishek Banerjee; Naomi Habib; Yinqing Li; John Trombetta; Mriganka Sur; Feng Zhang
Journal:  Nat Biotechnol       Date:  2014-10-19       Impact factor: 54.908

4.  Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones.

Authors:  Keiichiro Suzuki; Chang Yu; Jing Qu; Mo Li; Xiaotian Yao; Tingting Yuan; April Goebl; Senwei Tang; Ruotong Ren; Emi Aizawa; Fan Zhang; Xiuling Xu; Rupa Devi Soligalla; Feng Chen; Jessica Kim; Na Young Kim; Hsin-Kai Liao; Chris Benner; Concepcion Rodriguez Esteban; Yabin Jin; Guang-Hui Liu; Yingrui Li; Juan Carlos Izpisua Belmonte
Journal:  Cell Stem Cell       Date:  2014-07-03       Impact factor: 24.633

Review 5.  A cut above the rest: targeted genome editing technologies in human pluripotent stem cells.

Authors:  Mo Li; Keiichiro Suzuki; Na Young Kim; Guang-Hui Liu; Juan Carlos Izpisua Belmonte
Journal:  J Biol Chem       Date:  2013-12-20       Impact factor: 5.157

6.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

7.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype.

Authors:  Hao Yin; Wen Xue; Sidi Chen; Roman L Bogorad; Eric Benedetti; Markus Grompe; Victor Koteliansky; Phillip A Sharp; Tyler Jacks; Daniel G Anderson
Journal:  Nat Biotechnol       Date:  2014-03-30       Impact factor: 54.908

8.  Promoterless gene targeting without nucleases ameliorates haemophilia B in mice.

Authors:  A Barzel; N K Paulk; Y Shi; Y Huang; K Chu; F Zhang; P N Valdmanis; L P Spector; M H Porteus; K M Gaensler; M A Kay
Journal:  Nature       Date:  2014-10-29       Impact factor: 49.962

9.  CRISPR-mediated direct mutation of cancer genes in the mouse liver.

Authors:  Wen Xue; Sidi Chen; Hao Yin; Tuomas Tammela; Thales Papagiannakopoulos; Nikhil S Joshi; Wenxin Cai; Gillian Yang; Roderick Bronson; Denise G Crowley; Feng Zhang; Daniel G Anderson; Phillip A Sharp; Tyler Jacks
Journal:  Nature       Date:  2014-08-06       Impact factor: 49.962

10.  Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform.

Authors:  K Yoshimi; T Kaneko; B Voigt; T Mashimo
Journal:  Nat Commun       Date:  2014-06-26       Impact factor: 14.919
View more
  6 in total

Review 1.  Interspecies chimeric complementation for the generation of functional human tissues and organs in large animal hosts.

Authors:  Jun Wu; Juan Carlos Izpisua Belmonte
Journal:  Transgenic Res       Date:  2016-01-28       Impact factor: 2.788

2.  Emerging Trajectories for Next Generation Tissue Engineers.

Authors:  Daniel Naveed Tavakol; Sharon Fleischer; Thomas Falcucci; Pamela L Graney; Susan P Halligan; David L Kaplan; Gordana Vunjak-Novakovic
Journal:  ACS Biomater Sci Eng       Date:  2021-12-08

3.  Electrochemical Evaluation of Tumor Development via Cellular Interface Supported CRISPR/Cas Trans-Cleavage.

Authors:  Liangfen Cheng; Fuhan Yang; Longfei Tang; Lelin Qian; Xu Chen; Feng Guan; Juan Zhang; Genxi Li
Journal:  Research (Wash D C)       Date:  2022-04-06

Review 4.  Current and future therapies for inherited cholestatic liver diseases.

Authors:  Wendy L van der Woerd; Roderick Hj Houwen; Stan Fj van de Graaf
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

Review 5.  Neurogenethics: An emerging discipline at the intersection of ethics, neuroscience, and genomics.

Authors:  Turhan Canli
Journal:  Appl Transl Genom       Date:  2015-05-15

Review 6.  The Potential of iPSCs for the Treatment of Premature Aging Disorders.

Authors:  Claudia Compagnucci; Enrico Bertini
Journal:  Int J Mol Sci       Date:  2017-11-07       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.